BJL
BCRX icon

Brighton Jones LLC’s BioCryst Pharmaceuticals BCRX Stock Holding History

Brighton Jones LLC’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Buy
+16,926
New +$153K ﹤0.01% 1268

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
IMC Chicago
IMC Chicago Chicago, Illinois $419B AUM 72.04% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

Brighton Jones LLC's BCRX Position: Q2 2026 in Review

Brighton Jones LLC opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 16,926 shares worth $169K. The stake represents ﹤0.01% of the portfolio and ranks #1268 among its holdings.

154 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Brighton Jones LLC held 16,926 shares of BioCryst Pharmaceuticals worth $169K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Brighton Jones LLC position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1268 holding.
  • 154 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.